The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH. Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Cited by
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Van Herck, M., Vonghia, L., & Francque, S. (2017) · Nutrients · doi:10.3390/nu9101072 · Cited by 392
The ménage à trois of autophagy, lipid droplets and liver disease
Filali-Mouncef, Y., Hunter, C., Roccio, F., Zagkou, S., Dupont, N., Primard, C., Proikas-Cezanne, T., & Reggiori, F. (2022) · Autophagy · doi:10.1080/15548627.2021.1895658 · Cited by 361
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“DIetary MoDelS These are summarized in Table 1, and original references are cited in several reviews.(10,12,14,17-21,35,36) Overnutrition can be obtained by use of HFDs, but in most strains of mice body weights exceeding 40 g (obese for mice) are not achieved.”
InfluentialBoland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270
Self-citationPreclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G. J., Watt, M. J., & Karin, M. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 253
Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe−/−mice: role of SIRT1
Hua, Y. Q., Zeng, Y., Xu, J., & Xu, X. L. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153412 · Cited by 137
Boland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4904 · Cited by 129
Self-citationIn Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
“In general, the liver histology is quite similar to that in ob/ob mice, and db/db mice are also obese, hyperphagic, insulin-resistant, hyperglycemic and hyperinsulinemic and develop hepatic steatosis [109].”
BackgroundMethodInfluentialBeheshti, A., Chakravarty, K., Fogle, H., Fazelinia, H., Silveira, W. A. D., Boyko, V., Polo, S.-H. L., Saravia-Butler, A. M., Hardiman, G., Taylor, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55869-2 · Cited by 90
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
Hwang, S., Yun, H., Moon, S., Cho, Y. E., & Gao, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751802 · Cited by 84
An update on animal models of liver fibrosis
Wu, S., Wang, X., Xing, W., Li, F., Liang, M., Li, K., He, Y., & Wang, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160053 · Cited by 71
Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010060 · Cited by 70
“The CDHFD/NaNO2 model was well-suited to assess these effects since it presents a portal hypertensive phenotype with hyperdynamic circulation, whereas pure diet-induced NASH models often only show signs of steatohepatitis and mild fibrosis but lack PH [24].”
BackgroundInflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Myint, M., Oppedisano, F., De Giorgi, V., Kim, B.-M., Marincola, F. M., Alter, H. J., & Nesci, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04627-0 · Cited by 61
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10577-2 · Cited by 53
Self-citationA decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30
Metadata
- Authors
- Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 22
- Issue
- 11
- Pages
- 1707-1718
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2730267177
- Cited by
- 270
- References
- 126
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.